Herpes simplex virus infection, Acyclovir and IVIG treatment all independently cause gut dysbiosis

Chandran Ramakrishna1, Stacee Mendonca1, Paul M. Ruegger2, Jane Hannah Kim2, James Borneman2*, Edouard M. Cantin1*

1 Department of Molecular Immunology, Beckman Research Institute of City of Hope, Duarte, California, United States of America, 2 Department of Microbiology and Plant Pathology, University of California, Riverside, California, United States of America

* ecantin@coh.org (EMC); borneman@ucr.edu (JB)

Abstract

Herpes simplex virus 1 (HSV) is a ubiquitous human virus resident in a majority of the global population as a latent infection. Acyclovir (ACV), is the standard of care drug used to treat primary and recurrent infections, supplemented in some patients with intravenous immunoglobulin (IVIG) treatment to suppress infection and deleterious inflammatory responses. As many diverse medications have recently been shown to change composition of the gut microbiome, we used Illumina 16S rRNA gene sequencing to determine the effects of ACV and IVIG on the gut bacterial community. We found that HSV, ACV and IVIG can all independently disrupt the gut bacterial community in a sex biased manner when given to uninfected C57BL/6 mice. Treatment of HSV infected mice with ACV or IVIG alone or together revealed complex interactions between these drugs and infection that caused pronounced sex biased dysbiosis. ACV reduced Bacteroidetes levels in male but not female mice, while levels of the Anti-inflammatory Clostridia (AIC) were reduced in female but not male mice, which is significant as these taxa are associated with protection against the development of graft versus host disease (GVHD) in hematopoietic stem cell transplant (HSCT) patients. Gut barrier dysfunction is associated with GVHD in HSCT patients and ACV also decreased Akkermansia muciniphila, which is important for maintaining gut barrier functionality. Cumulatively, our data suggest that long-term prophylactic ACV treatment of HSCT patients may contribute to GVHD and also potentially impact immune reconstitution. These data have important implications for other clinical settings, including HSV eye disease and genital infections, where ACV is given long-term.

Introduction

Herpes Simplex Virus type 1 (HSV), a ubiquitous human virus is the major cause of HSV encephalitis (HSE), the most prevalent sporadic encephalitis resulting from either primary infection or reactivation of latent virus. However, despite improved diagnostic procedures and
Effective antiviral therapies, most HSE survivors have persistent neurological impairments, including memory and behavior disturbances, dysphasia and seizures, and only 50–65% of these survivors return to independent living [1, 2]. A delay in initiating Acyclovir (ACV) treatment past the second hospital day is associated with poor neurological outcomes [3, 4]. Recent clinical trials evaluating prolonged oral ACV/valaciclovir (VACV) treatment following standard 14-day intravenous ACV treatment reported improved neurocognitive outcomes in neonates but not adults for reasons that are obscure [5, 6]. Although, it is generally accepted that replication induced pathology underlies HSV related neurological dysfunction, supporting experimental or clinical evidence is lacking. Overwhelming evidence has linked inflammation to the development of various neurological disorders and neuropsychiatric diseases, including Alzheimer’s disease (AD), schizophrenia, autism spectrum disorder (ASD), multiple sclerosis (MS), Parkinson’s disease (PD), depression and anxiety [7–9].

Having unequivocally established that HSE arises from exaggerated CNS inflammatory responses and that the immunomodulatory activities of intravenous immunoglobulins (IVIG) can prevent HSE in a mouse model [10], we tested the hypothesis that persistent inflammation, which is documented in humans and mice after HSE [11–14], causes neurobehavioral impairments in survivors, that should be impeded by IVIG’s anti-inflammatory activity [10]. Compared to treatment of HSV infected mice with ACV or PBS alone, treatment with ACV+IVIG from day 4 pi reduced CNS inflammation and anxiety, consistent with our hypothesis. Strikingly, development of learning and memory (LM) deficits that were evident only in female PBS treated mice, were inhibited by ACV treatment and counterintuitively, aggravated by ACV+IVIG treatment. Treatment of infected male mice with ACV+IVIG also impaired LM compared to ACV or PBS alone, revealing that IVIG antagonized the beneficial effects of ACV [15]. Intriguingly, the differential antagonistic effects of ACV+IVIG on cognitive behavior in HSV infected mice, compared to ACV and PBS treatment alone, were reflected in differential serum proteomic profiles [15]. These reported antagonistic effects of ACV and IVIG on LM present a conundrum, since they are at odds with the known mechanisms of action of these drugs.

Rapidly accumulating evidence has revealed the critical role of the microbiome in regulating brain homeostasis and function, such that disruption of the gut bacteria community structure is being increasingly implicated in a variety of neurodegenerative and neuropsychiatric diseases. In an effort to gain insight into how HSV induces LM impairment and the paradoxical effects of ACV and IVIG, we investigated a role for the gut microbiota. HSV infection, ACV and IVIG were all associated with significant disruption of the gut bacterial community structure that was sex biased. Furthermore, treating HSV infected mice with either ACV or IVIG alone or both drugs together resulted in more pronounced sex-biased shifts in the gut bacterial community structure compared to uninfected mice. These results have significant clinical implications, particularly for patients who receive prolonged ACV or IVIG treatment.

Results

Equal numbers (n = 8) of female and male C57BL/6 mice were bilaterally inoculated with virulent HSV1 strain 17+ (1x10^5 PFU/eye) by corneal scarification as previously described [15]. At day 4 post infection (pi), ACV was administered at 1.25 mg / mouse by intraperitoneal injection (ip) daily for 3 days, while IVIG was given as single dose of 25 mg/mouse by ip injection on day 4pi [15]. Mock treated control mice were treated identically except administered PBS instead of ACV or IVIG. Fresh fecal pellets (n = 1-2/ mouse) were collected on day 7 pi and stored at -80°C until processed for Illumina 16S rRNA gene sequencing to determine the effects of infection and drug treatment on the gut microbiome. Normal male and female mice
differed in gut bacteria composition and unexpectedly, HSV ocular infection caused further shifts in the gut bacteria community and amplified this sex difference, as shown in a PCoA plot of Hellinger beta diversity distance values for infected compared to uninfected male and female mice (Fig 1A; P<0.05, Adonis Tests). In addition, HSV infection had a greater effect on gut bacterial communities in males (P = 0.003) compared to females (P = 0.011) (Fig 1A). Significant differences were observed at the phyla level, particularly for firmicutes (Fig 1B) with more marked differences evident at the species level for *Clostridium aerotolerans* and other clostridial species, for example *Clostridium XIVa* that ferment carbohydrates in the gut resulting in production of short chain fatty acids (SFCs) that contribute to barrier integrity and also exhibit anti-inflammatory properties (Fig 1C). A notable difference was also observed for *Akkermansia muciniphila* that has many health promoting activities, including maintaining gut barrier health (Fig 1C).

Treating HSV infected mice with ACV from day 4 pi for three days resulted in even more drastic shifts in the gut bacteria composition and exaggerated sex differences (Fig 2A), than for infection alone. Considerable abundance changes were evident at the Phyla level for *Bacteroidetes, Firmicutes* and *Verrucomicrobia* (Fig 2B) and at the species level (Fig 2C). Notably, ACV dramatically decreased the abundance of *Verrucomicrobia* in both female and male infected mice (edgeR, FDR-adjusted P = 0.000) (Fig 2B). At finer taxonomic levels, notable abundance changes included an ACV-associated increase in a member of the *Porphyromonadaceae* in male (edgeR, FDR-adjusted P = 0.044) but not female infected mice (Fig 2C). While *Akkermansia muciniphila* abundance was not significantly changed by infection in either male or female mice (Fig 1C), ACV treatment resulted in total suppression of this species in female mice (edgeR, FDR-adjusted P = 0.000) and a marked reduction in male mice (edgeR, FDR-adjusted P = 0.010) (Fig 2C). For uninfected mice, ACV treatment was associated with reductions in several taxa including several *Alistipes* species such as *A. shahii*, and members of the *Porphyromonadaceae* and *Lachnospiraceae* in female but not male mice (S1 Fig). There are many other similar changes in species abundance that are differentially impacted by ACV treatment in a sex-biased manner, indicative of complex interactions between infection, ACV effects on infected host cells, and bacteria, as well as metabolites produced by bacterial metabolism of ACV.

Treatment of uninfected mice with ACV+IVIG (Fig 3A) and IVIG alone (Fig 3B) also shifted the gut bacteria community composition with a notable marked sex effect as determined by a beta diversity analysis (Adonis tests, P<0.05). Similar results were obtained for infected mice for these same two treatment groups (Adonis tests P<0.005) (Fig 3C and 3D). ACV treatment alone changed gut bacterial communities in infected mice (Adonis tests P<0.005) (Fig 2A) but not in uninfected mice. All of these results are also shown in one plot in S2 Fig and the associated statistics are in S1 Table.

IVIG treatment in infected female (edgeR, FDR-adjusted P = 0.000) but not male mice was associated with a major reduction in the *Verrucomicrobia* (Fig 4A). Similarly, IVIG treatment reduced the most common species in the *Verrucomicrobia, Akkermansia muciniphila*, in infected female mice (edgeR, FDR-adjusted P = 0.000) but not male mice (Fig 4B). The abundance of other bacterial species was differentially altered by IVIG treatment in uninfected male and female mice including *Bacteroides acidifaciens* (edgeR, FDR-adjusted P<0.000) (Fig 4B). The response to IVIG was distinct in HSV infected mice, and the complex interactions between infection, ACV and IVIG were also evident at the phyla and species levels and were strongly sex biased as well (Fig 4A and 4B). For example, a member of the *Porphyromonadaceae* was increased by ACV treatment in male infected mice (edgeR, FDR-adjusted P = 0.002) but decreased by IVIG treatment (edgeR, FDR-adjusted P<0.026) in uninfected female mice (Fig 4B). In a similar vein, *C. aerotolerans* abundance increased markedly with IVIG treatment.
Fig 1. Fecal bacteria from HSV-infected and uninfected mice. A. Principal-coordinate analysis (PCoA) of Hellinger beta diversity distance values generated from 16S rRNA gene sequences. All four groups are different (P < 0.05, Adonis tests). The number of mice (n) in each genotype-microbiota group are shown in parentheses. B. Bacteria phyla associated with HSV-infected and uninfected mice. C. Bacterial species (or higher taxa) associated with HSV-infected and uninfected mice. Females = _F and Males = _M.

https://doi.org/10.1371/journal.pone.0237189.g001
in infected male mice (edgeR, FDR-adjusted P < 0.000) but this same treatment decreased this bacterium in uninfected male mice (edgeR, FDR-adjusted P < 0.007) (Fig 4B).

Patients with hematologic and other malignancies have benefited immensely from allogeneic hematopoietic stem cell transplantation (allo-HSCT or HSCT), which can be a potent...
curative immunotherapy. However, life threatening complications such as graft-versus-host disease (GVHD), relapse, and infections that include reactivated HSV and VZV limit its application [16]. HSV and varicella zoster (VZV) reactivation has been successfully suppressed by prophylactic ACV treatment, though ACV-resistant (ACVr) HSV is an emerging problem [17, 18]. Long term ACV prophylactic treatment is now routine for HSCT patients, because it was found to correlate with reduced HSV and ACVr HSV disease in those treated for longer than 1 year [19].

Given this routine clinical practice, we evaluated the effects of ACV on fecal bacteria, because gut microbes have been implicated in GVHD pathophysiology and because we hypothesize that ACV contributes to the development of GVHD by changing the gut microbiota. First, we identified gut bacterial changes in humans with GVHD [20–30]. Next, we determined whether the ACV-induced changes that we detected in this mouse study matched those GVHD-associated changes. Whenever we identified taxa that were altered in both types of studies, the direction of the change was the same, and it was consistent with our hypothesis that ACV contributes to the development of human GVHD by changing the gut microbiota. In the following, we describe these results, and we note that these ACV-induced changes were only observed in the HSV-infected mice and not in the uninfected mice.
Fig 4. Fecal bacterial from HSV-infected and uninfected mice treated and not treated with ACV and/or IVIG. A and B. Bacteria phyla and species (or higher taxa), respectively, associated with HSV-infected and uninfected mice treated and not treated with ACV, IVIG, or ACV +IVIG. Females = _F and Males = _M.

https://doi.org/10.1371/journal.pone.0237189.g004
Reduced levels of several taxa belonging to the phylum Bacteroidetes have been shown to be associated with GVHD, indicating that these gut bacteria may play a protective role. In a pediatric study, GVHD patients had lower levels of the family Bacteroidaceae and the genus Parabacteroides [30]. In a longitudinal study, pediatric patients that had lower levels of Bacteroidetes prior to HSCT were more likely to develop GVHD [24]. In our study, all three if these taxa were reduced by ACV treatment in male but not female mice (Fig 5A).

Reduced levels of anti-Inflammatory Clostridia (AIC) have also been detected in human GVHD patients [20, 23–25, 27–30], indicating that these gut bacteria may play a protective role. This terminology was first introduced by Piper et al. [31] in the context of short bowel syndrome, and then introduced to the GVHD literature by Simms-Waldrip et al. [30]. AIC taxa include members of the families Clostridiaceae, Erysipelotrichaceae, Eubacteriaceae, Lachnospiraceae and Ruminococcaceae. In a pediatric study, decreases in Blautia and Clostridium bolteae were associated with the development of GVHD [30]. In an adult study, lower levels of Blautia, Blautia hansenii, and Blautia stercoris were associated with the development of GVHD [28]. In a longitudinal study, reduced levels of the Blautia before HSCT was shown to be a predictive marker for the development of GVHD [27]. In our study, all of these taxa were reduced by ACV treatment in female but not male mice (Fig 5B).

In a more detailed analysis of AIC bacteria, we observed that while HSV infection increased the abundance of Blautia hansenii only in males, ACV treatment reduced its abundance in females but had no effect on its abundance in males (S3 Fig). Remarkably, a dramatic increase in B. hansenii in uninfected females was observed after IVIG treatment, and this increase was abrogated by ACV (compare NoHSV_F, NoHSV_IVIG_F and NoHSV_ACVplusIVIG_F) (S3 Fig), a result that supports sex-based differential effects of these drugs. However, during HSV infection, both IVIG and ACV reduced B. hansenii in females, whereas only IVIG reduced abundance in males. Interestingly, HSV infection significantly increased the abundance of the AIC genera Blautia, Allobaculum, and Clostridium XVIII but not Turicibacter in both males and females (S4 Fig). ACV treatment of HSV infected female mice resulted in significant decreases in the abundances of 4 AIC genera: Blautia, Allobaculum, Clostridium XVIII and Turicibacter, whereas in infected males, ACV decreased the abundance of Marvinbryantia and Oscillibacter (S3 Fig). In addition, ACV increased the abundance of Turicibacter in uninfected females but not males.

Finally, the two most abundant operational taxonomic units (OTUs), which exhibited a change in their relative abundances due to ACV treatment, were assigned to the family Porphyromonadaceae and the species A. muciniphila (Fig 5C). While we did not find these taxa associated with GVHD in prior human studies, GVH has been associated with intestinal barrier dysfunction [32–36]. Supporting our hypothesis that ACV contributes to the development of GVHD by changing the gut microbiota, members of the Porphyromonadaceae have been shown to cause gut barrier dysfunction [37, 38], and our Porphyromonadaceae OTU was increased in its abundance by ACV. In addition, A. muciniphila was decreased by ACV treatment in our study, and it has been shown to strengthen gut barrier functioning [39–41].

**Discussion**

Our intention in this brief report is to alert the scientific community and especially clinicians to the fact that HSV infection, the antiviral drug ACV, and the immunomodulatory biological agent, IVIG, can all independently result in significant perturbations of the gut bacterial communities. Our data reveal complex interactions between HSV infection and ACV or/and IVIG treatment that result in marked alterations to gut bacterial communities. Although the clinical
Fig 5. Fecal bacterial from HSV-infected and uninfected mice treated and not treated with ACV. A and B. Fecal bacterial taxa that were changed in both human GVHD studies and by ACV in this study. A and B. Members of the Bacteroidetes and AIC, respectively. C. The two most abundant bacterial OTUs. The only pairwise differences shown are between ACV treated and untreated mice for each sex (edgeR, FDR-adjusted P values < 0.05). Bars = standard error. Females = _F and Males = _M.

https://doi.org/10.1371/journal.pone.0237189.g005
consequences of these changes have not yet been elucidated, they could have profound implications in several settings including HSCT-associated GVHD.

Though the mechanisms by which ocular HSV infection causes gut dysbiosis are unclear, neuroinflammatory mechanisms and effects on the enteric nervous system via synaptically connected brainstem neuronal circuits can be envisaged [15, 42]. Indeed, recent paradigm-shifting reports reveal that peripheral neurons, including nociceptive and sensory neurons, can directly sense and respond to environmental alarms by releasing neuropeptides that can regulate immune responses in target organs including the gut [43, 44]. Persistence of gut dysbiosis was not evaluated here, but results from a behavioral study alluded to earlier imply long-term effects of infection and drug treatment on gut bacterial ecology could be involved and should be investigated [15]. Sex biased effects on HSV induced dysbiosis merit further study, as these may involve microglial responses to HSV infection and the microglial compartment is known to be regulated by the microbiota in a sex biased manner [45–47].

The mechanism by which ACV, the standard antiviral for HSV infections, changes the gut microbiota likely involves its uptake into bacteria. ACV is preferentially phosphorylated by the viral encoded thymidine kinase (Tk) resulting in cell retention and eventual incorporation into viral DNA resulting in inhibition of viral replication via DNA chain termination. Because Tk is conserved in numerous bacterial species, ACV can be taken up and incorporated into DNA, resulting in bactericidal effects [48–51]. Indeed, early studies on DNA replication mechanisms relied on labeling bacterial DNA with tritiated thymidine and many bacterial taxa can be imaged using nucleoside analogues such as 1-(2-deoxy-2-fluoro-D-arabinofuranosyl)-5-[125I] iouracil ([125I]FIAU) that are substrates for HSV Tk [52–55]. Incorporation of [methyl-3H]thymidine into DNA has been unequivocally demonstrated for members of the Clostridium genus [56] and our data show ACV reduced the abundance of the Blautia genus (order Clostridiales; [57]) Blautia hansenii, Blautia stercoris, and Clostridium bolteae in females but not males. Additionally, interrogating the NCBI reference genome sequence for Blautia hansenii confirmed the presence of a thymidine kinase enzyme. Our data are therefore consistent with ACV causing dysbiosis by, at least in part, inhibiting the growth of various bacteria taxa via the Tk mechanism, though other mechanisms involving bacterial metabolism of ACV cannot be excluded. Clearly, the mechanisms by which ACV affects gut bacterial ecology are complex, as evidenced by the sex-biased effects.

We also explored the effects of IVIG treatment alone and in combination with ACV in HSV-infected and uninfected mice, because IVIG has been used to treat HSV encephalitis (HSE) and is also a frontline therapy for autoimmune encephalitis, which is triggered by HSE and other insults [58–60]. Moreover, IVIG is being evaluated in a randomized control trial for children with all-cause encephalitis to determine whether neurological outcomes are improved, compared to standard antiviral therapy alone, which is similar to our behavioral study that generated paradoxical results [15, 61]. Reports that IVIG’s antigenic repertoire includes reactivities to a variety of gut commensal antigens and metabolites have increased recently [62–64], which is consistent with a report that gut commensals can somehow trigger systemic IgG responses under homeostatic conditions that protect against systemic infection [65, 66]. We speculate that by neutralizing bacterial/host antigens/metabolites, IVIG is able to influence host immunity, the nervous system, and other physiological processes, resulting in perturbation of gut bacteria ecology. We speculate that the disparate and complex effects of ACV and IVIG alone and in combination on the gut bacteria ecology likely account for their antagonistic effects on cognitive behavior in mice latently infected with HSV that we alluded to earlier [15].

This study has several limitations. Being exploratory in nature, analyses of the gut bacteria were done at a single time point immediately after infection or drug treatment, rather than as...
a longitudinal study that would have provided information on the persistence of the dysbiotic state as well as mechanistic insights as to how HSV, ACV and IVIG provoke dysbiosis. Ideally, the effects of ACV should be tested in latently infected mice, since virtually all HSCT patients harbor latent HSV. However, because HSV infection alone disrupts the gut bacterial community, assessing the effects of ACV on the gut bacteria community organization in latently infected mice would likely be difficult. Because ACV was given ip to mice, but is usually administered orally to HSCT patients [67], its effects on the gut bacteria community organization maybe underestimated in our study.

Notwithstanding these caveats, our finding that ACV treatment of HSV infected mice decreased the relative abundances of several bacterial taxa is important because these bacteria have been negatively correlated with the induction of and mortality from GVHD in HSCT patients [24, 27, 28, 30]. These results are also consistent with our hypothesis that ACV contributes to the development of GVHD by changing the gut microbiota. In the context of allo-HSCT, GVHD occurs when donor immune cells recognize recipient tissues as foreign, leading to immune-mediated damage to several organs and tissues including the gastrointestinal tract. This has led researchers to posit that the reduction of anti-inflammatory bacteria such as AIC contribute to GVHD pathology [30]. The results from our study extend this hypothesis to include ACV treatment as a putative contributor to GVHD, because ACV reduced AIC bacteria in the gut. ACV treatment also decreased the relative abundances of several members of the Bacteroidetes, some of which have been shown to exhibit anti-inflammatory properties [68–71]. More relevantly, the capsular polysaccharide A (PSA) from Bacteroides fragilis reduced HSV-associated mortality in mice by dramatically reducing immune-mediated inflammation [72]. In addition, the two most abundant OTUs identified in our study, whose relative abundances were positively (Porphyromonadaceae) and negatively (A. muciniphila) correlated with ACV treatment, have been shown to weaken [37, 38] and strengthen [39–41] gut barrier function, respectively. These results provide an additional link between ACV treatment and GVHD, because barrier dysfunction, which can cause systemic inflammation, is a hallmark of GVHD [32–36]. Finally, long-term ACV prophylaxis initiated early after HSCT might also impair immune reconstitution based on results from a study of antibiotic depletion of gut bacteria in a murine model of syngeneic bone marrow transplantation [73]. These tantalizing results warrant independent validation and further detailed studies using a murine autologous BMT model to more rigorously evaluate the impact of long-term ACV prophylaxis on GVHD and engraftment. Ideally, such future studies should be performed with mice harboring wild microbiota, because several recent reports show that immune responses in mice with wild microbiomes model human immune responses more closely than conventional mice with SPF microbiota [74–76].

Materials and methods

Ethics statement

All animal procedures were performed with prior approval of the City of Hope Institutional Animal Care and Use Committee (IACUC) under protocol # 07043 and within the framework of the Guide for the Care and Use of Laboratory Animals. C57BL6/J (B6) were bred in the vivarium at City of Hope.

Mouse studies

Master stocks of HSV1 strain 17+ composed of only of cell-released virus were prepared and titered using mycoplasma-free CV-1 monolayers. HSV1 strain 17+ was obtained from Dr. Chris Preston, MRC Virology, University of Glasgow, Scotland and CV1 cells were obtained
from the ATCC, Rockville, MD, USA. Single use aliquots of virus in Hanks balanced salt solution supplemented with 2% fetal bovine serum were stored at -80˚C; stock virus appropriately diluted in PBS was used for inoculation. Male and female mice, 6–8 weeks of age, were infected with HSV1 17β, a virulent strain or mock infected with PBS. Mice were sedated with ketamine (60 mg/kg) and xylazine (5 mg/kg) prior to HSV inoculation by corneal scarification. B6 mice were bilaterally inoculated with 1x 10^5 PFU per eye and monitored daily as previously described [15, 77].

**Administration of Acyclovir and intravenous immunoglobulins**

ACV obtained from (APP Pharmaceuticals, Schaumburg, IL) was given at 50 mg/kg of body weight by intraperitoneal (ip) injection daily for 3 days starting on day 4 pi and PBS was given according to the same schedule to control mice. IVIG (Carimune, NF) obtained from CSL Behring (King of Prussia, PA, USA) was given ip as a single 0.5 ml dose (25 mg/mouse) on day 4 pi or it was given in combination with a 3-day course of ACV; control mice were given 0.5 ml PBS in lieu of IVIG. We randomly selected 5 healthy mice for microbiome analysis, which provided sufficient statistical power for subsequent analysis of gut bacterial abundance and diversity. At day 7 pi after collection of fecal pellets the mice were euthanized by CO_2 exposure delivered from a compressed CO_2 gas cylinder. Unconsciousness was achieved usually within 2–3 minutes as indicated by lack of respiration and faded eye color, but CO_2 exposure was continued for an additional 15 minutes to prevent unintended recovery.

**Illumina bacterial 16S rRNA gene sequencing**

Illumina bacterial 16S rRNA gene libraries were constructed as follows. PCRs were performed in an MJ Research PTC-200 thermal cycler (Bio-Rad Inc., Hercules, CA, USA) as 25 μl reactions containing: 50 mM Tris (pH 8.3), 500 μg/ml bovine serum albumin (BSA), 2.5 mM MgCl_2, 250 μM of each deoxynucleotide triphosphate (dNTP), 400 nM of the forward PCR primer, 200 nM of each reverse PCR primer, 1 μl of DNA template, and 0.25 units JumpStart Taq DNA polymerase (Sigma-Aldrich, St. Louis, MO, USA). PCR primers 515F (GTGCCAGCMGCCGCGGTAA) and 806R (GGACTACHVGGGTWTCTAAT) were used to targeted the 16S rRNA gene containing portions of the hypervariable regions V4 and V5, with the reverse primers including a 12-bp barcode [78]. Thermal cycling parameters were 94˚C for 5 min; 35 cycles of 94˚C for 20 s, 50˚C for 20 s, and 72˚C for 30 s, and followed by 72˚C for 5 min. PCR products were purified using the MinElute 96 UF PCR Purification Kit (Qiagen, Valencia, CA, USA).

**16S rRNA gene data processing**

We used the UPARSE pipeline for de-multiplexing, length trimming, quality filtering and operational taxonomic units (OTU) picking using default parameters or recommended guidelines that were initially described in [79] and which have been updated at https://www.drive5.com/uchime/manual/uparse_pipeline.html. Briefly, after demultiplexing, sequences were trimmed to a uniform length of 249 bp, then filtered at the recommended 1.0 expected error threshold. Sequences were then dereplicated and clustered into zero-radius OTUs using the UNOISE3 algorithm [80], which also detects and removes chimeric sequences; this method is based on making OTUs at 100% identity. An OTU table was then generated using the otutab command. OTUs having non-bacterial DNA were identified by performing a local BLAST search [81] of their seed sequences against the nt database. OTUs were removed if any of their highest-scoring BLAST hits contained taxonomic IDs within Rodentia, Viridiplantae, Fungi,
or PhiX. Taxonomic assignments to the OTUs were performed with SINTAX [82] using RDP Classifier 16S training set number 16 [83] as the reference database.

16S rRNA gene data analyses
Beta diversity was measured using QIIME 1.9.1 [84] to calculate a Hellinger beta diversity distance matrix, which was depicted using principle coordinates analysis (PCoA), and statistically assessed by performing Adonis tests. Statistical differences among the taxa were determined using edgeR [85, 86]. Taxa relative abundance figures were made using Prism (GraphPad, La Jolla, CA). Comparative analyses of the bacterial taxa between human GVHD studies and our mouse study excluded sequence-selective qPCR, because the selectivity of such assays is questionable given the conserved nature of the 16S rRNA gene, and because the results of such studies are not typically validated by sequence analyses. The bacterial sequences have been deposited in the National Center for Biotechnology Information (NCBI)'s Sequence Read Archive (SRA) under the BioProject Accession Number PRJNA549765.

Supporting information
S1 Checklist. The ARRIVE guidelines checklist.
(PDF)

S1 Fig. Fecal bacteria from uninfected mice treated and not treated with ACV. For each taxa, edgeR analyses determined that the only pairwise difference was between ACV treated and untreated uninfected female mice (FDR-adjusted P values < 0.05). Bars = standard error. Females = _F and Males = _M.
(PDF)

S2 Fig. Beta diversity analysis of Fecal bacteria from HSV-infected and uninfected mice treated and not treated with ACV and/or IVIG. Principal-coordinates analysis (PCoA) of Hellinger beta diversity distance values generated from 16S rRNA gene sequences. The number of mice (n) in each genotype-microbiota group are shown in parentheses. Females = _F and Males = _M.
(PDF)

S3 Fig. Fecal Blautia hansenii from HSV-infected and uninfected mice treated and not treated with ACV and/or IVIG. Pairwise differences are shown by horizontal lines (edgeR, FDR-adjusted P values < 0.05). Bars = standard error. Females = _F and Males = _M.
(PDF)

S4 Fig. Fecal bacterial genera from HSV-infected and uninfected mice treated and not treated with ACV and/or IVIG. Pairwise differences are shown by horizontal lines (edgeR, FDR-adjusted P values < 0.05). Bars = standard error. Females = _F and Males = _M.
(PDF)

S1 Table. The numbers in the cells are P values obtained from Adonis tests of the Hellinger beta diversity matrix.
(PDF)

Author Contributions
Conceptualization: Edouard M. Cantin.
Data curation: Edouard M. Cantin.
Formal analysis: Chandran Ramakrishna, Paul M. Ruegger, James Borneman, Edouard M. Cantin.

Investigation: Chandran Ramakrishna, Stacee Mendonca, Jane Hannah Kim, James Borneman.

Methodology: Chandran Ramakrishna, James Borneman, Edouard M. Cantin.

Project administration: Edouard M. Cantin.

Resources: James Borneman, Edouard M. Cantin.

Software: Paul M. Ruegger.

Supervision: Edouard M. Cantin.

Writing – original draft: Edouard M. Cantin.

Writing – review & editing: Chandran Ramakrishna, James Borneman.

References


